Senseonics Holdings, Inc. filings document the public-company disclosures of a medical technology issuer commercializing implantable continuous glucose monitoring products for diabetes care. Its Form 8-K reports furnish operating results and business updates for Eversense CGM systems, including commercialization activity, clinical or regulatory disclosures, product integrations and financial outlook commentary.
The company’s regulatory record also covers capital-structure and financing matters, including public offerings of common stock and pre-funded warrants and amendments to debt arrangements. Proxy materials disclose board elections, executive compensation votes, auditor ratification, authorized-share proposals and equity incentive plan matters. A Form 25 filing documents the voluntary withdrawal of Senseonics common stock from listing and registration on NYSE American.
ROEDER DOUGLAS A reported acquisition or exercise transactions in this Form 4 filing.
Senseonics Holdings director Douglas A. Roeder received a stock award of 2,751 common shares as compensation. The grant was made in lieu of quarterly cash retainer fees and was valued at $14,745.36, based on a $5.36 closing share price on July 1, 2026.
After this non‑market grant, Roeder directly holds 157,238 shares of Senseonics common stock, reflecting routine director compensation rather than an open-market purchase or sale.
Fiorentino Edward reported acquisition or exercise transactions in this Form 4 filing.
Senseonics Holdings, Inc. director Edward Fiorentino received a grant of common stock as part of his non-employee director compensation. He was issued 2,635 shares of common stock in lieu of quarterly cash retainer fees, based on a value of $14,123.60 at a price of $5.36 per share, which was the closing price on July 1, 2026. Following this award, he directly owns 85,974 shares of Senseonics common stock.
Senseonics Holdings director Steven Edelman received a stock grant as part of his board compensation. He acquired 2,402 shares of common stock on July 1, 2026 at a reference price of $5.36 per share, issued under the company’s non-employee director compensation policy in lieu of quarterly cash retainer fees.
The grant value was $12,874.72, based on the Nasdaq Global Select Market closing price on that date. Following this award, Edelman directly holds 91,083 shares of Senseonics common stock, reflecting routine equity-based director compensation rather than an open-market purchase.
Senseonics Holdings, Inc. Chief Medical Officer Francine Kaufman reported a routine share disposition related to taxes. On the vesting of restricted stock units, 4,010 shares of common stock were withheld at a reference value of $7.18 per share to satisfy withholding tax obligations. After this tax-withholding event, Kaufman directly holds 177,057 shares of Senseonics common stock. This transaction does not represent an open-market purchase or sale, but an automatic mechanism to cover taxes tied to equity compensation.
Senseonics Holdings, Inc. Chief Operating Officer Mukul Jain reported a routine tax-related share disposition. On the Form 4, 16,194 shares of common stock at a value of $7.18 per share were withheld to satisfy withholding tax obligations when restricted stock units vested, rather than sold in the open market.
After this withholding, Jain directly holds 500,863 shares of Senseonics common stock. The transaction reflects compensation-related tax withholding and does not represent an open-market purchase or sale decision.
Senseonics Holdings, Inc. Chief Financial Officer Frederick T. Sullivan reported a routine tax-related share disposition. On the vesting of restricted stock units, 5,397 shares of common stock were withheld to satisfy withholding tax obligations, rather than sold on the open market.
After this tax-withholding disposition, Sullivan directly holds 226,477 shares of common stock. The filing reflects compensation-related share vesting mechanics, not an active purchase or sale decision in the market.
Senseonics Holdings, Inc. reported that GC & Corp. Development Advisor Kenneth L. Horton had 9,545 shares of common stock withheld on June 15, 2026 to cover tax obligations from vesting restricted stock units. After this tax-withholding event, he directly holds 285,512 common shares.
Senseonics Holdings, Inc. reported an insider equity update for Chief Commercial Officer Brian B. Hansen. On the reported date, 5,420 shares of common stock were disposed of at $7.18 per share to satisfy withholding tax obligations tied to vesting restricted stock units. This was a tax-withholding transaction rather than an open-market sale. After this event, Hansen directly owned 126,937 shares of Senseonics common stock.
Senseonics Holdings, Inc. reported an insider equity transaction by President and CEO Timothy T. Goodnow. On the reported date, 32,598 shares of common stock were withheld at a price of $7.18 per share to cover withholding tax obligations tied to the vesting of restricted stock units. This was not an open-market sale but a tax-withholding disposition. After this transaction, Goodnow directly held 1,143,748 shares of Senseonics common stock.
Senseonics Holdings, Inc. has completed the previously announced local asset purchase agreements with Ascensia Diabetes Care for its commercial Eversense continuous glucose monitoring (CGM) activities in several European markets. These transactions cover Eversense CGM commercial assets in Germany, Spain, Sweden and Italy.
The asset purchases in Germany, Spain and Sweden closed on June 1, 2026, and the purchase related to Italy closed on June 8, 2026, with the transfer effective for finance and accounting purposes as of June 1, 2026. This shifts ownership of these commercial assets from Ascensia to Senseonics and its affiliates in the covered countries.